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Abstract
Background: The development of next-generation sequencing (NGS) technologies has a great impact in the
human variation detection given their high-throughput. These techniques are particularly helpful for the evaluation
of the genetic background in disorders of complex genetic etiology such as Hirschsprung disease (HSCR). The
purpose of this study was the design of a panel of HSCR associated genes as a rapid and efficient tool to perform
genetic screening in a series of patients.
Methods: We have performed NGS-based targeted sequencing (454-GS Junior) using a panel containing 26
associated or candidate genes for HSCR in a group of 11 selected HSCR patients.
Results: The average percentage of covered bases was of 97 %, the 91.4 % of the targeted bases were covered
with depth above 20X and the mean coverage was 422X. In addition, we have found a total of 13 new coding
variants and 11 new variants within regulatory regions among our patients. These outcomes allowed us to re-evaluate
the genetic component associated to HSCR in these patients.
Conclusions: Our validated NGS panel constitutes an optimum method for the identification of new variants in
our patients. This approach could be used for a fast, reliable and more thorough genetic screening in future
series of patients.
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Background
Hirschsprung disease (HSCR, OMIM 142623) is a devel-
opmental disorder occurring in 1 of 5.000 live births. It
is characterized by the absence of ganglion cells along
variable lengths of the distal gastrointestinal tract, which
results in tonic contraction of the aganglionic colon seg-
ment and functional intestinal obstruction. Such agan-
glionosis is associated with a delay in the entry of neural
crest-derived cells into the foregut, as well as a deferred
progression of enteric neural crest cells along the gut
[1–5]. Based on the length of the aganglionic region,
patients could be classified as short-segment (S-HSCR:
aganglionosis up to the upper sigmoid colon, 80 % of
cases), long-segment (L-HSCR: aganglionosis up to the
splenic flexure and beyond, 17 % of cases) and total co-
lonic aganglionosis forms (TCA, 3 % of cases) [1]. HSCR
most commonly presents sporadically with reduced
penetrance and male predominance, although it can be
also familial with an autosomal dominant or autosomal
recessive model of inheritance. HSCR occurs as an iso-
lated trait in 70 % of cases and it is associated with other
congenital malformation syndromes in the remaining
30 % [1, 3, 4].
Therefore, HSCR is regarded as a disorder with com-
plex genetic basis, in which the contribution of several
different loci acting in an additive or multiplicative
manner is usually required to cause the disease. The
RET proto-oncogene is the major susceptibility gene for
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HSCR since more than 80 % of identified mutations as-
sociated with HSCR are located in this gene, including
both coding and noncoding variants [6–8]. Mutations in
RET coding sequence account for up to 50 % or 7–20 %
of familial and sporadic cases, respectively [1]. Other
genes encoding members of a variety of signalling
pathways related to enteric nervous system (ENS) devel-
opment, have been also reported to be related to HSCR
(GDNF, NRTN, PSPN, EDNRB, EDN3, ECE1, NTF3,
NTRK3, SOX10, PHOX2B, L1CAM, ZFHX1B, KIAA1279,
TCF4, PROK1, PROKR1, PROKR2, GFRA1, NRG1, SEMA-
PHORIN 3A, SEMAPHORIN 3C and SEMAPHORIN 3D).
However, mutations in these genes only explain the mi-
nority forms of L-HSCR/TCA or syndromic forms of the
disease [9–15].
The development of next-generation sequencing (NGS)
technologies has a great impact in human mutation detec-
tion procedures given their high throughput nature. In the
last 10 years we have witnessed a tremendous increase in
sequencing speed paralleled by costs falling dramatically
by 10.000–100.000 fold compared to the classical Sanger
method [16–19].
The 454-GS Junior (Roche) is a NGS sequencer that
leads to a rapid sample processing. In 2012, a study of
three class III semaphorin as candidate genes based on
amplicon sequencing (454-GS Junior Platform) was per-
formed in 47 HSCR samples. They reported 37 sequence
variants, where 10 were unique to HSCR patients, in-
cluding 5 missense mutations in these three genes that
may be potentially involved in the pathogenesis of HSCR
[11]. More recently, PCR-based RainDance technology
and 454 FLX sequencing have been applied to analyze
62 genes in 20 Chinese HSCR patients and 20 Chinese
non HSCR controls, reporting 5 rare damaging variants
likely involved in the disease [20].
Here, we have used the 454 GS-Junior Platform to per-
form NGS-based targeted sequencing to validate the de-
sign of our panel. With such purpose, we selected a
group of 11 patients carrying a total of 18 different vari-
ants, previously identified by Sanger method, in any of
the genes included in the panel. After panel validation,
we determined the set of candidate variants carried by
our patients in these HSCR-associated genes.
Methods
Patients and control subjects
Our study involved a total of 11 Spanish HSCR index
patients, comprising a male: female ratio equal to 10:1
with different phenotypic features (two with TCA, four
with L-HSCR, four with S-HSCR and one with not avail-
able data) (Table 1). All patients were referred to our
Department of Genetics, Reproduction and Fetal Medi-
cine. Additionally, we had a total of 26 DNA samples
from available family members of our patients that were
used to perform subsequent segregation analysis of the
new identified variants.
We also included a group of 200 healthy control sub-
jects comprising unselected, unrelated, race, age, and
sex-matched individuals, to determine the allelic fre-
quency of the new variants in our population.
All subjects underwent peripheral blood extraction for
genomic DNA isolation using MagNA Pure LC system
(Roche, Indianapolis, IN) according to the manufac-
turer’s instructions. DNA samples were stored at −80 °C
until needed for further analyses.
Ethics statement
A written informed consent was obtained from all the
participants for clinical and molecular genetic studies.
The study was approved by the Ethics Committee for
clinical research in the University Hospital Virgen del
Rocío (Seville, Spain) and complies with the tenets of
the declaration of Helsinki.
Design of the capture panel and estimation of panel yield
A capture panel of HSCR related genes was designed by
our group and the final file was submitted to Roche
NimbleGen (Roche NimbleGen Inc., Madison, WI, USA)
to synthesize the hybridization probes. The probes cov-
ered 235 regions (exons and closer introns) of 26 known
HSCR genes with a total of 44.196 bp in design region
(Additional file 1). Flanking sequences were also detected
by our sequencer, raising the number to 62.515 bp.
Sensitivity and specificity of the panel were calculated
according to methods previously described [21]. Regard-
ing sensitivity, it was calculated as the percentage of
variants previously detected by conventional Sanger se-
quencing that the panel is able to detect. This was tested
with 18 variants previously diagnosed (SNVs, insertions
and deletions). The specificity was calculated as the per-
centage of variants detected by the panel that conform
to sequencing quality controls and are validated by
Sanger sequencing, and therefore are true variants.
DNA library preparation and targeted sequencing
Library preparation was performed according to the
manufacturer’s protocol [SeqCap_EZ_Library_LR_Guide_
v2.0 and SeqCap_EZ_LR_DoubleCapture_Rapid_v1p4_2
protocols (Roche NimbleGen Inc., Madison, WI, USA)].
Briefly, 500 ng of genomic DNA was fragmented among
500–1500 bp, then end repaired and ligated with adaptors.
The library was amplified by precapture linker-mediated
PCR (LM-PCR). After purification, 1 μg LM-PCR product
was hybridized to custom designed SeqCap EZ Library
(Roche NimbleGen, Madison, WI, USA). After washing,
amplification was performed with post-capture LM-PCR.
This process was repeated twice. The final concentration
of each captured library was measured with Quant-iT
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Table 1 Description of the 11 patients included in the study, detailing all of the variants previously detected







RET CS065611 c.1263 + 2 T > A - 10:g.43604680 T > A; intronic Splicing
site
268X Detected
NTRK3 rs139392904 c.1933C > T p.Arg645Cys 15:g.88472622G > A; CDS −/+ 311X Detected

















RET rs17158558 c.2944C > T p.Arg982Cys 10:g.43620335C > T; CDS −/+ 146X Detected












PSPN rs199881560 c.271C > T p.Arg91Cys 19:g.6375505G > A; CDS +/+ 13X Detected







NTRK3 No c.1229 + 21delTCC - 15:g.88670477-79delGGA; intronic Intronic 105X Detected





NTF3 rs1805149 c.226G > A p.Gly76Arg 12:g.5603607G > A; CDS −/− 1247X Detected
9 NA (male) Sporadic, non
syndromic
NRTN No c.199G > A p.Ala67Thr 19:g.5827789G > A; CDS −/+ 7X Detected

















L1CAM CM981156 c.2077G > A p.Gly693Arg X:g.153132856C > T; CDS +/+ 221X Detected
TCA total colonic aganglionosis, L-HSCR long-segment HSCR, S-HSCR short-segment HSCR, NA not available data, Chr chromosome, cvg mean coverage, CDS coding DNA sequence
(1) c.93_410delGGTCGATCTTCAGGGCCA













PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA,
USA) and diluted at 106 molecules/μl. To perform the
emulsion PCR, a 0.7 molecule per bead ratio was chosen.
After enrichment, a maximum of 250.000 beads were
sequenced on 454-GS Junior (Roche) sequencer according
to the manufacturer’s protocol (Sequencing Method
Manual GS Junior, Titanium Series).
Bioinformatic analyses of the sequencing results
Sequencing reads were aligned to human hg19 reference
by GS Reference Mapper software (Roche, version 2.7).
Improperly mapped reads were filtered out with the
SAMtools package. The BEDtools package was applied
to analyze the coverage and the percentage of covered
bases. Variant calling was performed with GATK (Genome
Analysis Toolkit, version 1.4 for SNVs and 1.0 for INDELs).
A minimum of 6X coverage was required for every detected
variant; at least 25 % of total reads were needed to support
the variant allele and variants with a disequilibrium be-
tween forward or reverse < 15 % were removed. Sequence
variation annotation was performed using VARIant ANa-
lysis Tool (version 2.1.0) [22]. Annotated variants present in
NCBI dbSNP [23] and 1000 Genomes project [24] data-
bases with a minor allele frequency (MAF) > 0.05 were
discarded. The remaining variants were compared with hu-
man mutation databases such as HGMD [25] and ClinVar
[26], to detect known disease-associated variants previously
identified by Sanger method. Additional novel sequence
variants identified were further prioritized considering their
inheritance and type of changes. Candidate variants were
obtained based on two criteria:
1) New variants only present in one patient:
In a first step of the analysis, we discarded variants
registered on Ensembl [27] and dbSNP databases.
Only exonic and closer intronic regions were
selected. All new detected variants were searched in
1000 Genomes and Exome Variant Server [28] to
confirm their status of “new variant”.
2) Variants registered in databases:
Variants with MAF < 0.05 present in Biomart [29]
and Variant Effect Predictor [27] were considered.
All data were managed with the online web tool
Galaxy Project [30–32].
Assessment of the pathogenicity of variants
The in silico prediction tools used were: SIFT [33] and
PolyPhen2 [34], to establish the pathogenicity of amino
acidic changes; the ENCODE Project [35] to determine
the location of variants in regulatory regions; The Berlekey
Drosophila Genome project [36], to study splice-site
changes; MUpro [37] and I-Mutant2.0 [38] for prediction
of protein stability and UniProt [39] to determine the pro-
tein domains where the variants were located.
Criteria to select patients after NGS analyses for further
discussion
After NGS analyses, we selected patients based on their
new variants detected by this study, in compilation with
their previous known genetic background. We excluded
those ones who: 1) carry one or several previously de-
scribed variant(s) that could explain the phenotype of
the patient and/or 2) the new variants detected in this
study were predicted as benign or they were located at
regulatory regions which would require additional stud-
ies to ascertain their role in the gene function.
Sanger validation and segregation analyses
All putative HSCR-related variants and 4 panel regions
with insufficient coverage by NGS were validated by
Sanger sequencing. DNA sequences were obtained from
Ensembl and Primer3 [40, 41] was used for primer de-
sign (data and conditions available under request). The
products were sequenced by an automated sequencer
3730 DNA analyzer (Applied Biosystems®). Variants were
analyzed with the program DNASTAR® Lasergene 8 Seq-
Man Pro™ (DNAstar, Madison, WI) [42]. All variants
were tested for segregation in all available family mem-
bers by Sanger sequencing and analyzed in a group of
200 healthy control subjects.
Dataset was submitted to the European Nucleotide
Archive with an accession number PRJEB7384.
Results and discussion
Panel yield
The average percentage of covered bases was 97 % and
the median percentage of reads on target of our panel
was 82.5 %. The high mean coverage obtained (422X)
could be explained by the small size of the panel (less
than 50.000 base pairs) (Table 2). From the 235 regions
contained in the panel, 231 regions had a minimum
coverage above 6X. Moreover, 91.3 % of bases had
coverage above 20X. Both sensitivity and specificity were
of 94 and 82.8 % respectively.
Validation of the panel and detection of new variants
The two main goals of this approach were both the val-
idation of our panel, using variants previously identified
by Sanger method in our series of patients (Table 1), and
the discovery of new variants that could help to further
define the complex genetic basis of the pathology in
each patient (Table 3). An average of 200 different SNVs
was detected in each patient. After the application of
stringent filter criteria, a range of 1 to 4 candidate vari-
ants per patient were selected. The SNV validation rate
was 88 %. In addition, 6 INDELs were selected for fur-
ther analysis and 3 were validated by Sanger.
After exclusion of all false-positives, validation and
segregation analyses were performed. A total of 13 new
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different coding variants potentially involved in HSCR
were obtained and only 5 were previously described. In
addition, we identified 11 new non-coding variants
in regulatory regions, most of them with an in silico
prediction of affecting enhancer, promoter and/or
CCCTC-binding sites (CTCF) (Table 3). It has been
previously determined the critical role of regulatory
variants in intronic regions, mainly a common RET
variant (rs2435357; 10:g.43086608 T > C) located in a gut-
specific RET enhancer element in intron 1 [8]. A higher
focus on these kind of variants would be interesting in fur-
ther studies because most of NGS targeted studies are
limited to present coding variants, but non-coding vari-
ants located in regulatory regions can also affect the gene
expression and thereby, the phenotype of disease.
Contributions of new variants
The previously known genetic background of our pa-
tients, together with the new variants found, allowed us
to define more precisely the molecular basis of the
Table 2 Summary of statistics of targeted sequencing in
our patients
Patient N° reads Reads on target (%) Covered bases (%) cvg
1 203871 84.4 97.3 445X
2 165770 84.9 96.7 358X
3 169514 83.4 97.6 343X
4 131085 80.8 96.7 252X
5 241836 83.7 96.8 492X
6 236746 83.4 98.0 611X
7 239404 84.0 97.3 553X
8 227925 84.1 97.3 522X
9 165282 71.5 97.5 279X
10 178037 83.5 96.9 346X
11 215702 83.9 96.9 446X
Mean 197742.9 82.5 97.2 422X
cvg mean coverage
Table 3 New variants detected by NGS-based targeted sequencing in all patients
Patient Gene Chr position ID Changes MAF In silico prediction
1 ECE1 1:g.21573855 A > G rs1076669 c.1013C > T/p.Thr338Ile 0.04 - / -
ECE1 1:g.21551614 G > A rs3026905 c.2004 + 129C > T 0.02 -
2 GFRA3 5:g.137588322 C > T - c.*335 G > A <0.01 Low activity region
RET 10:g.43600210delGCACAGTCA rs546164092 c.625 + 2134delGCACAGTCA 0.004 Enhancer
RET 10:g.43600325delCC rs144431581 c.625 + 2244delCC >0.05 Enhancer
GFRA1 10:g.117884822 T > A - c.665A > T/p.Gln222Leu <0.01 - / +
3 SEMA3D 7:g.84651849 G > T rs141893504 c.1272C > A/p.His424Gln <0.01 + / +
GFRA1 10:g.118030415 A > T rs8192662 c.253 T > A/p.Tyr85Asn 0.02 + / +
EDNRB 13:g.78493201 C > T - c.-51-442 C > T <0.01 Promoter
GDNF 5:g.37835932 G > A - c.-26-1008 G > A - -
4 ECE1 1:g.21564631 C > T rs141146885 c.1376G > A/p.Ser459Asn <0.01 - / -
5 PHOX2B 4:g.41749629 A > G rs191239994 c.242-76 T > C <0.01 Enhancer
SEMA3C 7:g.80378343 T > A rs201228749 c.1713A > T/p.Ala571Ala - New splicing site
GFRA2 8:g.21640172 C > T - c.280C > T/p.Arg94Cys <0.01 + / +
6 PHOX2B 4:g.41747630 G > A rs186778106 c.*194C > A 0.01 Enhancer
NRG1 8:g.32406656 C > T rs148585725 c.100 + 312C > T 0.01 Promoter /CTCF binding site
NRG1 8:g.32617713C > T rs79223941 c.1086-5C > T 0.01 -
7 NRG1 8:g.32611970 G > T rs74942016 c.772G > T/p.Val258Leu 0.02 + / +
8 GFRA1 10:g.118030415 A > T rs8192662 c.253 T > A/p.Tyr85Asn 0.02 + / +
10 NRG1 8:g.32611970 G > T rs74942016 c.772G > T/p.Val258Leu 0.02 + / +
ECE1 1:g.21571475 G > A rs28368004 c.1242 + 7C > T 0.01 CTCF binding site
GFRA1 10:g.118031734 G > C rs45568534 c.-193C > G 0.01 Enhancer
11 EDNRB 13:g.78492763 G > C - c.*988C > G - Predicted promoter
NTF3 12:g.5541624 C > G rs71578945 c.18 + 116C > G <0.01 Enhancer
Description of all new variants found in this study, except for patient 9, who was not found to carry any new additional variant by NGS
In silico prediction: amino acidic changes (− / −) benign for SIFT and Polyphen; (− / +) damaging in one; (+ / +) damaging in both
Non-coding regions evaluated by the ENCODE project database
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disease in 4 of the 11 patients (numbers 2, 3, 5 and 8)
(Fig. 1). The remaining 7 cases were not found to carry
any new relevant variant that contributed to better ex-
plain their phenotype.
Of note, patients 2, 3 and 5 presented alterations
in class-III semaphorin and in GFRα receptor genes
simultaneously (Fig. 1 and Table 3). Several families of
molecules implicated in attractive and repulsive guid-
ance are involved in axon guidance, such as semaphorins
and GDNF. Some crucial mechanisms in HSCR are me-
diated by GDNF, which requires GFRα1 as a co-receptor
for optimal ligand binding and activation, and both act
as chemoattractants to promote neurite outgrowth [43,
44]. Based on these previous studies, we hypothesize that
an additive effect of variants in both semaphorins (in-
volved in cell migration) and GFRα receptors (related to
proliferation and cell survival) may act as modifier in
HSCR. Recently, it has been demonstrated that Sema3C/
3D signaling is an evolutionarily conserved regulator of
ENS development and its dys-regulation leads to enteric
aganglionosis [45]. Paratcha and Charoy functionally
showed the interplay between GDNF and GFRα, as well
as SEMAs and GDNF signaling during axon guidance,
respectively. Charoy et al. analyzed single and double
Fig. 1 Family trees of patients 2, 3, 5 and 8. All previously identified variants and the new ones found in this study were included. Symbols: V = variant;
arrow = patient included in the study; genotypes: − =wildtype allele; + = non-standard allele; * = not available DNA
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mutant mouse models to confirm that gdnf is the princi-
pal trigger of Sema3B, acting with NrCAM. In addition,
genetic and in vitro experiments provide evidence that
this gdnf effect is mediated by NCAM/GFRα1 signaling.
In conclusion, our observations suggest a potential com-
bination of variants in these genes that could contribute
to disease, based on the demonstrated interplay among
this type of molecules, although further functional and
statistical studies would be required for confirmation.
Patient 2 (L-HSCR) presented a previously known
SEMA3D p.Arg634Gln variant, with maternal inherit-
ance and a damaging/benign in silico prediction by
SIFT/Polyphen respectively. We have identified four
new heterozygous variants. The most relevant one was
GFRA1 p.Gln222Leu, with paternal inheritance and an
in silico prediction of tolerated/possibly damaging
(Fig. 1, Tables 3 and 4). This patient could fit in the
additive model proposed for HSCR based on the pa-
ternal and maternal inheritance of his variants. As we
mentioned before, the joint effect of variations in
SEMAs and GFRAs genes could help to gain insight
into the genetic basis of the disease in this patient.
Patient 3 (L-HSCR) was previously known to carry
PROK1 p.Arg48Trp variant with a probably damaging in
silico prediction. Our group previously published that
PROK1 may participate in a complementary signalling to
the RET/GFRα1/GDNF pathway, giving support to the
proliferation/survival and differentiation of precursor
cells during ENS development [14]. From the new vari-
ants detected in this patient (Fig. 1, Tables 3 and 4) and
based on both the in silico probably damaging prediction
and the described interconnection among these genes,
we suggest that GFRA1 p.Tyr85Asn could interact with
SEMA3D p.His424Gln and thus, together with PROK1
p.Arg48Trp variant, would contribute to better under-
stand the genetic basis of HSCR in this case.
Patient 5 (S-HSCR) had a previously known variant in
PROKR1 p.Lys354Asn with an in silico prediction of tol-
erated/probably damaging. In this study, he was found
to carry a synonymous variant in SEMA3C p.Ala571Ala,
predicted as pathogenic due to the alteration of an ex-
onic splicing enhancer site (ESE) (Fig. 1, Tables 3 and 4).
The ESE sites are targeted essentially by Serine/Argin-
ine-rich proteins defining the splice-sites within the
exons [46]. Genomic variations causing aberrant splicing
may represent up to 50 % of all mutations that lead to
gene dysfunction and pathology [47–49]. Furthermore,
patient 5 showed a new variant in GFRA2 p. Arg94Cys
with damaging prediction (Table 4). GFRA2 had been
previously evaluated as a candidate gene for HSCR in
just one previous study [50]. Six coding variants were
identified, but only 2 led to an amino acidic change at
protein level. Both changes were located at the C-
terminus of GFRA2, a region which is not crucial for
GFRα binding to either RET or GDNF family members.
The authors concluded that GFRΑ2 variants were un-
likely to represent a common genetic cause or modifier
of the HSCR phenotype. In contrast, our analyses have
revealed a heterozygous C > T variant in exon 2 of
GFRA2 gene, that causes a highly conserved arginine-94
residue substitution to a cysteine residue in the cysteine
rich domain of the receptor. In silico predictions suggest
that p.Arg94Cys variant would decrease the stability of
protein structure and it could be a non-neutral change.
Table 4 In silico predictions of functional effect for most relevant variants in patients 2, 3, 5 and 8
Patient Variants SIFT/Polyphen MUpro I-Mutant 2.0 Uniprot
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S score, CS confidence score, RI reliability index
(−) = not located at a specific domain
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Our results would suggest that GFRA2 might be recon-
sidered as a candidate gene for HSCR.
Finally, patient 8 (L-HSCR), who presented a known
variant in NTF3 p.Gly76Arg (benign prediction), was
found to carry GFRA1 p.Tyr85Asn (pathogenic predic-
tion) (Fig. 1, Tables 3 and 4) as well. Different studies
have described the association of polymorphisms with
HSCR, which might suggest the possibility to consider
GFRA1 p.Tyr85Asn as a putative susceptibility factor in
this patient [51, 52]. However, to confirm this hypoth-
esis, further case-control studies in additional series of
patients are required.
Conclusions
We have validated the high capacity of the NGS targeted
sequencing to detect SNVs, which accounts for most of
the variants, pathogenic or not, in the genes included in
the panel. Many of the possible insertions and deletions
detected by NGS with the 454 GS-Junior (around a
thousand for each patient) were false positives due to
the limitations of the technique to detect this type of
variants [53]. Our study also provides a higher coverage
of the included regions and a manageable amount of
data to be analyzed than other studies [54]. Additional
newly discovered HSCR-linked genes could be included in
panels similar to ours due to their flexibility. Also, this de-
sign could be adapted to different sequencing platforms.
Our validated NGS panel has resulted in a fast, effect-
ive and easy method to characterize the genetic back-
ground in our patients and to identify new variants that
could be associated to HSCR. Our results expand the
previously known set of variants carried by these pa-
tients and further support the feasibility of using NGS
targeted sequencing in diseases with complex genetic
basis such as HSCR. Moreover, this technique may help
in the understanding of the genetic and molecular basis of
the disease, providing a new tool in clinical practice to
simultaneously analyze many genes as well as to identify
several molecular events contributing to the phenotype.
Additional file
Additional file 1: Detailed description of covered regions in our
panel of genes. (XLS 53 kb)
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